| Metric | Value (₹ Cr) | vs Q2 FY25 |
|---|---|---|
| Revenue | 596.70 | 9.6% |
| Total Income | 621.80 | 8.8% |
| Expenditure | 483.50 | 3.1% |
| PBT | 138.30 | 24.5% |
| Net Profit | 98.10 | 25.0% |
| OPM | 12.13% | 6.03pp |
| NPM | 15.78% | 3.40pp |
| EPS | 11.60 | 25.3% |
Dr. Lal PathLabs Reports 10.7% Revenue Increase, 19.3% PAT Increase in Q3 FY25
30 Jan 2025 · 30 Jan 2025, 07:37 pm
Summary
Dr. Lal PathLabs Limited, a leading diagnostic and related healthcare service provider, has announced its financial results for the quarter ended December 31, 2024. The company reported a 10.7% increase in revenue, a 9.6% increase in EBITDA with a margin of 25.8%, and a significant 19.3% increase in PAT with a margin of 16.4%. The company also declared a third interim dividend of Rs. 6 per share for FY25.
Key Highlights
- 1
Revenue increased by 10.7% in Q3 FY25
- 2
EBITDA increased by 9.6% with a margin of 25.8%
- 3
PAT increased by 19.3% with a margin of 16.4%
- 4
Third Interim Dividend of Rs. 6 per share for FY25
Management Comments
Dr. Lal PathLabs Ltd
Not provided in the document.
Informational and educational content only. Not investment advice.